Company: KROS
Filing Date: 2025-08-06
Form Type: 8-K
Source: 0001664710-25-000071
Chunk: 7

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 8-K
Item: Item 8.01
Chunk 7
---
Item 8.01 Other Events.

On August 6, 2025, the Company issued a press release concerning recent organizational changes to the Company, including the appointment of Dr. Lerner, Ph. D., as the Company's Chief Scientific Officer, effective as of the Start Date, and the cessation of Mr. Rovaldi's employment, effective as of the Separation Date.

A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.